# Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

> **NCT04337632** · PHASE3 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 338 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Doxorubicin Hydrochloride Liposome Injection+carboplatin
- **DRUG:** paclitaxel +carboplatin

## Key facts

- **NCT ID:** NCT04337632
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 338 (ESTIMATED)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04337632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04337632, "Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04337632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*